Q1 Collaboration Revenue Rises 15% to $17.7M as Costs Drop 20%
Theravance posted Q1 collaboration revenue of $17.7 million, up 15% year-over-year, and saw U.S. YUPELRI net sales of $62.4 million, a 7% increase with 19% hospital channel growth after settling generic litigation through 2039. Operating expenses (excluding restructuring) fell ~20% year-over-year, with cash of $395 million and no debt.
1. Collaboration Revenue and Sales Performance
Theravance’s Q1 2026 collaboration revenue reached $17.7 million, a 15% increase from Q1 2025, driven by its 35% share of net YUPELRI sales and improved operating leverage. Viatris-reported U.S. YUPELRI net sales were $62.4 million, up 7% year-over-year, with hospital channel doses pulled growing 19%, and GSK’s TRELEGY net sales hit $873 million, a 2% rise.
2. Resolution of Hatch-Waxman Litigation
In March, Theravance and Viatris settled all Hatch-Waxman litigation relating to YUPELRI with Mankind Pharma, establishing a licensed generic launch date of April 23, 2039. This agreement removes major generic overhang and secures YUPELRI’s franchise stability through the settlement term.
3. Cost Reduction and Restructuring Progress
Organizational restructuring initiatives have reduced operating expenses (excluding restructuring charges) by approximately 20% year-over-year in Q1 2026. The company remains on track to cut total operating costs by about 60%, targeting $60–70 million of annualized savings to be fully realized in Q3 2026.
4. Strong Financial Position and Strategic Review
Theravance ended Q1 with $395 million in cash and no debt, reinforcing its robust balance sheet. An independent Strategic Review Committee is actively evaluating alternatives, including potential sale or other value-maximizing transactions, while maintaining confidence in achieving a $100 million 2026 milestone payment from TRELEGY net sales.